Share
1,666 Posts.
lightbulb Created with Sketch. 161
clock Created with Sketch.
22/06/17
13:51
Share
Originally posted by RNClarke
↑
I bought some more today, this is confirmation US results will be a great success.
Some posters have mentioned some good points especially regarding pneumonia results. These results firstly are much more robust than previously reported.
The most important numbers are the ones in bold. These results include the patients cough, runny nose, fever and age. These will all be requirements by the FDA when using ResAppDx. It is well known we need 70% from these US results, well all are 90% or above bar the pneumonia numbers which is still at 81%.
The reason the overall percentage agreement for pneumonia (81%) is due to the low negative percentage agreement (NPA), and this is mentioned as being subjective depending on the clinician and due to overlap.
The March 2016 results said ResAppDx was able to differentiate between viral and atypical. It can still do so, but all pneumonia has been bundled into one bucket. You can't have FDA approval for just atypical or just viral pnuemonia. It will all be under 'pneumonia'.
For an instant diagnostic tool, these results are exceptional.
Expand
Exactly RN, it's a quick and instant diagnostic tool, and will be combined in the whole diagnosis of the patient, not just a stand-alone, results are great
DD